KarenLynn(Riedl)ReckampMDMS
Oncology • Los Angeles, CAThoracic Cancer
Director, Division of Medical Oncology Associate Director, Clinical Research, Cedars-Sinai Cancer
Dr. Reckamp is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8700 Beverly Blvd
Los Angeles, CA 90048Phone+1 310-423-7197- Is this information wrong?
Summary
- Dr. Karen Reckamp is an oncologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. She received her medical degree from University of Chicago Pritzker School of Medicine and has been in practice over 15 years. She specializes in hematologic oncology and thoracic cancer and is experienced in lung cancer, thymic malignancies and mesothelioma.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2001 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
- PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
- Ponatinib in Advanced NSCLC w/ RET Translocations Start of enrollment: 2013 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.Marion Ferreira, Mary W Redman, Karen L Reckamp> ;Journal of Thoracic Oncology. 2023 Dec 1
- Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, Melina E Marmarelis, Carolyn J Presley, Karen L Reckamp, Hina Khan, Mary Jo Fidler, Christine M Bestvina, Julie Brahm...> ;Lung Cancer. 2023 Dec 1
- 1 citationsPhase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall, Nasser H Hanna, Young Kwang Chae, Marianna Koczywas, Irene B Helenowski, Jyoti D Patel> ;The Oncologist. 2024 Jan 5
- Join now to see all
Lectures
- Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.2019 ASCO Annual Meeting - 6/1/2019
- Brigatinib for Metastatic ALK Positive Non-Small Cell Lung Cancer. FDA Approvals and Their Incorporation into Clinical Practice2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
April Research HighlightsApril 28th, 2023- SWOG S2302 Pragmatica-Lung Study Opens to Enrollment, a Model for Easier, More Representative Clinical TrialsApril 12th, 2023
- Advances in Non-Small-Cell Lung Cancer TreatmentDecember 12th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
